The live attenuated subgroup B respiratory syncytial virus vaccine candidate RSV 2B33F is attenuated and immunogenic in chimpanzees, but exhibits partial loss of the ts phenotype following replication in vivo

Virus Research

Volumn 59, Issue 1, 1999, Pages 13-22

  Crowe Jr , James E ^a   Randolph, Valerie ^b   Murphy, Brian R ^a  

^a Sect Clin and Exp Neuropsychol   (United States)

^b PFIZER INC   (United States)

Author keywords

Chimpanzees; Live attenuated vaccine; Respiratory syncytial virus; Temperature sensitive mutant

Indexed keywords

RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ANIMAL EXPERIMENT; ARTICLE; CERCOPITHECIDAE; CHIMPANZEE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENETIC STABILITY; IMMUNOGENICITY; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INFECTION; VIRUS MUTANT; VIRUS REPLICATION;

ANIMALS; FEMALE; MALE; MUTATION; PAN TROGLODYTES; PHENOTYPE; PLAQUE ASSAY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; TEMPERATURE; VACCINES, ATTENUATED; VIRAL VACCINES; VIRUS REPLICATION;

CERCOPITHECUS AETHIOPS; PAN (APE); RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS; RODENTIA; SUBGROUP B; SYNCYTIAL VIRUS;

EID: 0032906894     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-1702(98)00118-X     Document Type: Article

References (29)

1. Bukreyev A., Whitehead S.S., Murphy B.R., Collins P.L. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J. Virol. 71:1997;8973-8982.
2. Coates H.V., Alling D.W., Chanock R.M. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am. J. Epidemiol. 83:1966;299-313.
3. Collins P.L., Hill M.G., Camargo E., Grosfeld H., Chanock R.M., Murphy B.R. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5 proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc. Natl. Acad. Sci.USA. 92:1995;11563-11567.
4. Collins P.L., McIntosh K., Chanock R.M. Respiratory syncytial virus. Fields B.N., Knipe D.M., Howley P.M. et al. Fields virology. 1996;1313-1351 Lippincott-Raven, New York.
5. Connors M., Crowe J.E. Jr., Firestone C.Y., Murphy B.R., Collins P.L. A cold-passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes. Virology. 208:1995;478-484.
6. Crowe J.E. Jr. Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development. Vaccine. 13:1995;415-421.
7. Crowe J.E. Jr., Collins P.L., London W.T., Chanock R.M., Murphy B.R. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine. 11:1993;1395-1404.
8. Crowe J.E. Jr., Bui P.T., Davis A.R., Chanock R.M., Murphy B.R. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine. 12:1994;783-790.
9. Crowe J.E. Jr., Bui P.T., London W.T., Davis A.R., Hung P.P., Chanock R.M., Murphy B.R. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine. 12:1994;691-699.
10. Crowe J.E. Jr., Bui P.T., Karron R.A., Clements M.L., Wright P.F., Chanock R.M., Murphy B.M. Live attenuated mutants of respiratory syncytial virus (RSV): In vitro markers and replication in mice or chimpanzees correlate with level of attenuation for seronegative human infants. Pediatr. Res. 37:1995;172A.
11. Crowe J.E. Jr., Bui P.T., Siber G.R., Elkins W.R., Chanock R.M., Murphy B.R. Cold-passaged, temperature sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine. 13:1995;847-855.
12. Crowe J.E. Jr., Bui P.T., Firestone C.Y., Connors M., Elkins W.R., Chanock R.M., Murphy B.R. Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates. J. Infect. Dis. 173:1996;829-839.
13. Crowe J.E. Jr., Firestone C.Y., Whitehead S.S., Collins P.L., Murphy B.R. Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene. Virus Genes. 13:1996;269-273.
14. Erwin J., Landon J.C. Spacious biocontainment suites for chimpanzees in infectious disease research. Erwin J., Landon J.C. Chimpanzee Conservation and Public Health: Environments for the Future. 1992;65-69 Diagnon/Bioqual, Rockville, MD.
15. Firestone C.Y., Whitehead S.S., Collins P.L., Murphy B.M., Crowe J.E. Jr. Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate. Virology. 225:1996;419-422.
16. Hsu K.H., Crowe J.E. Jr., Lubeck M.D., Davis A.R., Hung P.P., Chanock R.M., Murphy B.R. Isolation and characterization of a highly attenuated respiratory syncytial virus (RSV) vaccine candidate by mutagenesis of the incompletely attenuated RSV A2 ts-1 NG-1 mutant virus. Vaccine. 13:1995;509-515.
17. Juhasz K., Whitehead S.S., Bui P.T., Biggs J.M., Crowe J.E.Jr., Boulanger C.A., Collins P.L., Murphy B.R. The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein. J. Virol. 71:1997;5814-5819.
18. Kapikian A.Z., Mitchell R.H., Chanock R.M., Shvedoff R.A., Stewart C.E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89:1969;405-421.
19. Karron R.A., Buonagurio D.A., Georgiu A.F., Whitehead S.S., Adamus J.E., Clements-Mann M.L., Harris D.O., Randolph V.B., Udem S.A., Murphy B.R., Sidhu M.S. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc. Natl. Acad. Sci. USA. 94:1997;13961-13966.
20. Karron R.A., Wright P.F., Crowe J.E. Jr., Clements M.L., Thompson J., Makhene M., Casey R., Murphy B.R. Evaluation of two live cold-passaged, temperature-sensitive respiratory syncytial virus (RSV) vaccines in chimpanzees, adults, children and infants. J. Infect. Dis. 176:1997;1428-1436.
21. Kim H.W., Arrobio J.O., Pyles G., Brandt C.D., Camargo E., Chanock R.M., Parrott R.H. Clinical and immunological response of infants and children to administration of low-temperature adapted respiratory syncytial virus. Pediatrics. 48:1971;745-755.
22. Kim H.W., Arrobio J.O., Brandt C.D., Wright P., Hodes D., Chanock R.M., Parrott R.H. Safety and antigenicity of temperature sensitive (TS) mutant respiratory syncytial virus (RSV) in infants and children. Pediatrics. 52:1973;56-63.
23. Murphy B.R., Sotnikov A.V., Lawrence L.A., Banks S.M., Prince G.A. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine. 8:1990;497-502.
24. Murphy B.R., Park E.J., Gottlieb P., Subbarao K. An influenza A live attenuated reassortant virus possessing three temperature-sensitive mutations in the PB2 polymerase gene rapidly loses temperature sensitivity following replication in hamsters. Vaccine. 15:1997;1372-1378.
25. Prince G.A., Jenson A.B., Horswood R.L., Camargo E., Chanock R.M. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am. J. Pathol. 93:1978;771-791.
26. Pringle C.R., Filipiuk A.H., Robinson B.S., Watt P.J., Higgins P., Tyrrell D.A. Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers. Vaccine. 11:1993;473-478.
27. Randolph, V.B., Kandis, M., Broughan, J.H., McMullen, Y.M., Tatem, J.M., Weeks-Levy, C., 1994a. Ninth International Conference on Negative Strand Viruses 104. (Abstract).
28. Randolph V.B., Kandis M., Stemler-Higgins P., Kennelly M.S., McMullen Y.M., Speelman D.J., Weeks-Levy C. Attenuated temperature-sensitive respiratory syncytial virus mutants generated by cold adaptation. Virus Res. 33:1994;241-259.
29. Richman D.D., Murphy B.R. The association of the temperature-sensitive phenotype with viral attenuation in animals and humans: implications for the development and use of live virus vaccines. Rev. Infec. Dis. 1:1979;413-433.